PAGE 3/13 \* RCVD AT 1/26/2007 4:35:50 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-2/15 \* DNIS:2738300 \* CSID:301 319 7432 \* DURATION (mm-55):03-02

## RECEIVED CENTRAL FAX CENTER

JAN 2 6 2007

NC 84,381 App. No.10/706,088

## Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-17 are original claims, claims 18-26 are withdrawn.

## Claims List

## We claim:

- 1. (Original) A method to immunize a subject against malarial disease comprising:
  - a. administering to the subject a priming immunization preparation comprising one
    or more alphavirus replicons expressing a gene encoding a malarial antigen or
    combination of malarial antigens; and
  - subsequently administering to the subject a boosting immunization preparation comprising the malarial antigen or combination of malarial antigens, said
     preparation being selected from the group consisting of:
    - i. a recombinant non-alphavirus viral expression system encoding the malarial antigen;
    - ii. a preparation of the malarial protein antigen produced by recombinant DNA technology;
    - iii. a synthetic preparation of the malarial antigen;
    - iv. a malarial organism or extract thereof; and
    - v. a polynucleotide vector expressing the malarial antigen,

or a combination thereof.

- (Original) The method of claim 1 wherein the alphavirus replicon preparation is selected
  from the group consisting of RNA replicons, DNA replicons, and alphavirus replicon
  particles.
- (Original) The method of claim 2, wherein the alphavirus is selected from the group consisting of Venuezuelan Equine Encephalitis Virus, Semliki Forest Virus, and Sindbis Virus.
- 4. (Original) The method of claim 1, wherein the malarial antigen is selected from the group consisting of a full-length malarial antigen, an immunogenic fragment thereof, or an epitope derived from the malarial antigen, or a combination thereof.
- (Original) The method of claim 4, wherein the malarial antigen is selected from the group
  of malarial pathogens consisting of Plasmodium falciparum, Plasmodium vivax, and
  Plasmodium ovale.
- 6. (Original) The method of claim 5, wherein the malarial antigen is expressed at a stage of the malarial parasite life cycle selected from the group consisting of preerythrocytic, erythrocytic and transmission blocking.

- 7. (Original) The method claim 6, wherein the malarial antigen is selected from the group consisting of: PfCSP, PfEXP1, PfSSP2, PfLSA-1, PfLSA-3, PfMSP-1, PfAMA-1, PfEBA-175, PfMSP-3, PfMSP-4, PfMSP-5, PfRAP-1, PfRAP-2.
- (Original) The method of claim 1, wherein the non-alphavirus viral expression system is selected from the group consisting of poxvirus, adenovirus, adenoassociated virus, and retrovirus.
- 9. (Original) The method of claim 8, wherein the poxvirus is selected from the group consisting of cowpox, canarypox, vaccinia, modified vaccinia Ankara, or fowlpox.
- 10. (Original) The method of claim 1 wherein the malarial antigen is selected from the group of malarial parasites consisting of Plasmodium falciparum, Plasmodium vivax, and Plasmodium ovale.
- 11. (Original) The method of claim 1, wherein multiple boosting immunization doses are administered.

- 12. (Original) The method of claim 2, wherein the alphavirus replicon is a naked nucleic acid and the priming immunization preparation consists of 1, 2, 3, or 4 doses of the naked nucleic acid.
- 13. (Original) The method of claim 1, wherein the priming immunization preparation is administered by a route selected from the group consisting of: subcutaneously, intramuscularly, intradermally, mucosally, orally, and by specialized injection devices.
- 14. (Original) The method of claim 1, wherein the boosting immunization preparation is administered by a route selected from the group consisting of: subcutaneously, intramuscularly, intradermally, mucosally, orally, transcutaneously, and by specialized injection devices.
- 15. (Original) The method of claim 13 or 14 wherein the priming and boosting immunization preparations are administered by the same route.
- 16. (Original) The method of claim 13 or 14 wherein the priming and boosting immunization preparations are each administered by a different route.
- 17. (Original) A method to immunize a subject against malarial disease comprising:

- a. administering to the subject a priming immunization preparation comprising Venezuelan Equine Encephalitis replicon particles expressing a gene encoding a malarial antigen, wherein said malarial antigen is selected from the group consisting of a full-length malarial antigen, an immunogenic fragment thereof, and an epitope derived from the malarial antigen; and
- subsequently administering to the subject a boosting immunization preparation comprising the malarial antigen, said preparation comprising a poxvirus encoding the malarial antigen.
- 18. (Withdrawn) An immunogenic composition comprising two immunizing components, wherein the first immunizing component comprises alphavirus replicons expressing a gene encoding a malarial antigen, and wherein the second immunizing component comprises a preparation expressing the malarial antigen, said preparation being selected from the group consisting of
  - a recombinant non-alphavirus viral expression system encoding the malarial antigen;
  - a preparation of the malarial protein antigen produced by recombinant DNA technology;
    - i. a synthetic preparation of the malarial antigen;
    - ii. a malarial organism or extract thereof; and
    - iii. a polynucleotide vector expressing the malarial antigen,

or a combination thereof and wherein said malarial antigen is selected from the group consisting of a full-length malarial5 antigen, an immunogenic fragment thereof, and an epitope derived from the malarial antigen.

- 19. (Withdrawn) The immunogenic composition of claim 18, wherein said first immunizing component, said second immunizing component or both further comprise an adjuvant.
- 20. (Withdrawn) The immunogenic composition of claim 19 in combination with a pharmaceutically acceptable carrier.
- 21. (Withdrawn) An immunogenic composition comprising two immunizing components, wherein the first immunizing component comprises alphavirus replicon particles expressing a gene encoding a malarial antigen, and wherein the second immunizing component comprises a poxvirus vector expressing the malarial antigen.
- 22. (Withdrawn) The immunogenic composition of claim 21 wherein the alphavirus replicon particle is derived from VEE.
- 23. (Withdrawn) An immunogenic composition comprising two immunizing components, wherein the first immunizing component comprises alphavirus replicon particles

NC 84,381
App. No.10/706,088
expressing a gene encoding a malarial antigen, and wherein the second immunizing
component comprises a adenovirus vector expressing the malarial antigen.

- 24. (Withdrawn) The immunogenic composition of claim 23, wherein the alphavirus replicon particle is derived from VEE.
- 25. (Withdrawn) An immunogenic composition comprising two immunizing components, wherein the first immunizing component comprises alphavirus replicon particles expressing a gene encoding a malarial antigen, and wherein the second immunizing component comprises a plasmid DNA construct expressing the malarial antigen.
- 26. (Withdrawn) The immunogenic composition of claim 25, wherein the alphavirus replicon particle is derived from VEE.